[The clinical value of bleeding risk stratification].

Prediction of bleeding risk in patients receiving antithrombotic treatment has been repeatedly attempted and resulted in multiple risk models. Risk stratification can be used to personalize antithrombotic treatment to reduce bleeding complications. Although these risk models are validated and incorporated in the current guidelines, the feasibility and effectivity in daily practice remains questionable.

Outcomes with P2Y12 inhibitor monotherapy after PCI according to bleeding risk: A Bayesian meta-analysis.

Background: P2Y12 inhibitor monotherapy is a promising novel strategy to reduce bleeding complications compared to dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI). In order to personalise treatment with DAPT based on patients' bleeding risk, we compared outcomes after PCI between P2Y12 inhibitor monotherapy and DAPT according to bleeding risk.

Methods: A search for randomized clinical trials (RCTs) comparing P2Y12 inhibitor monotherapy after a short period of DAPT to standard DAPT after PCI was performed.